| Literature DB >> 33457341 |
Fariba Behnamfar1, Elham Arshad1.
Abstract
BACKGROUND: Postmenopausal bleeding might occur due to many benign and malignant underlying diseases. Differentiating between these diseases poses a great importance. This study was designed to compare the diagnostic value of pipelle endometrial sampling and curettage in patients with postmenopausal bleeding. Further, the results were compared with hysterectomy if performed.Entities:
Keywords: Dilatation and curettage; hysterectomy; menopause; metrorrhagia; postmenopause
Year: 2020 PMID: 33457341 PMCID: PMC7792876 DOI: 10.4103/abr.abr_28_20
Source DB: PubMed Journal: Adv Biomed Res ISSN: 2277-9175
Demographic variables of the participants
| Variables | Value |
|---|---|
| Age (years), mean±SD | 60.22±9.86 |
| BMI (kg/m2) | 27.63±3.62 |
| Menarche age (years) | 12.01±1.06 |
| Menopause age (years) | 50.13±3.48 |
| Parity | 4.68±2.41 |
| Waist–hip ratio | 0.85±0.04 |
| Endometrial thickness (mm) | 10.32±4.58 |
| Underlying disease (%) | |
| None | 26 (29.88) |
| Diabetes mellitus | 28 (32.2) |
| Hypertension | 48 (55.2) |
| Others | 12 (13.8) |
| Smoking | 2 (2.3) |
| Alcohol usage | 0 |
| History of PCO | 4 (4.6) |
| History of infertility | 2 (2.3) |
| History of HRT | 1 (1.1) |
| Self-history of malignancy | 3 (3.4) |
| Family history of malignancy | 0 |
SD: Standard deviation, BMI: Body mass index, PCO: Polycystic ovary syndrome
Pathological reports of different modalities
| Variables | Number % |
|---|---|
| Hysterectomy performed | 25 (29.1) |
| Hysterectomy pathology | |
| Normal | 5 (20) |
| Fibroid | 3 (12) |
| Endometrial adenocarcinoma Stage IA | 11 (44) |
| Endometrial adenocarcinoma Stage IB | 4 (16) |
| Leiomyosarcoma | 1 (4) |
| Serous adenocarcinoma | 1 (4) |
| Pipelle | |
| Atrophy | 23 (26.4) |
| Proliferative endometrium | 19 (21.8) |
| Secretary endometrium | 12 (13.8) |
| Polyp | 1 (1.1) |
| Atypical hyperplasia | 3 (3.4) |
| Carcinoma | 13 (14.9) |
| Endometritis | 1 (1.1) |
| Unsatisfactory | 3 (3.4) |
| Hyperplasia without atypical | 12 (13.8) |
| Curettage | |
| Normal | 1 (1.1) |
| Atrophy | 23 (26.4) |
| Proliferative endometrium | 19 (21.8) |
| Secretary endometrium | 13 (14.9) |
| Polyp | 1 (1.1) |
| Atypical hyperplasia | 3 (3.4) |
| carcinoma | 13 (14.9) |
| Endometritis | 1 (1.1) |
| Sarcoma | 1 (1.1) |
| Hyperplasia without atypical | 12 (13.8) |
Curettage (pipelle) sampling biopsy based on malignant and nonmalignant tumors in the hysterectomy pathology
| Curettage and pipelle sampling | Malignancy based on the pathology of hysterectomy | ||
|---|---|---|---|
| Yes ( | No ( | ||
| Atrophy | 0 | 6 | 0.001> |
| Polyp | 0 | 2 | |
| Atypical hyperplasia | 3 | 0 | |
| Carcinoma | 13 | 0 | |
| Sarcoma | 1* | 0 | |
*This patient was reported in the pipelle sampling biopsy unsatisfactory